Patent · US Active

Substituted pyridine and pyrazine BMI-1 inhibitors

US10584115B2 · kind B2 · utility

0Cited by

13References

17Claims

0Family size

Assignee

PTC THERAPEUTICS, INC. · US

Inventors

Ramil Baiazitov · East Brunswick Township, US
Soongyu Choi · Skillman, US
Wu Du · Cranbury, US
Seongwoo Hwang · Edison, US
Chang-Sun Lee · Montgomery, US
Ronggang Liu · Collegeville, US
Young-Choon Moon · Montgomery, US
Steven Paget · Dover, US
Hongyu Ren
Nadiya Sydorenko · Princeton, US
Richard Wilde · Newark, US

Key dates

Filing date	Nov 21, 2013
Grant date	Mar 10, 2020
Priority date	—
Expiry date	Nov 21, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07F5/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.